Merck KGaA just secured an FDA approval for its new once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, ...
Summit Therapeutics is gearing up for ivonescimab’s high-stakes FDA decision without its chief commercial officer (CCO) ...
ImmuniyBio is eyeing a move up the non-muscle invasive bladder cancer (NMIBC) treatment line for its immunotherapy Anktiva. ...
Following a back-and-forth with the Pentagon this year, contracting juggernaut WuXi AppTec appears to have largely evaded its ...
Johnson & Johnson is gearing up to expand the commercial reach of Caplyta after scoring a second phase 3 victory in bipolar ...
Vertex has decided to lay off 78 employees at Crinetics Pharmaceuticals following its $10 billion acquisition of the ...
Eli Lilly is keeping pace amid its Foundayo launch with a new celebrity spokesperson and fresh campaign for the oral obesity drug. | The new celebrity partnership is the second for Lilly's oral GLP-1 ...
Shortly after locking down a world-first approval in China, Bayer is bringing its groundbreaking stroke prevention drug ...
The FDA has launched a safety investigation into Novartis’ gene therapy Zolgensma following reports of tumors in patients, as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results